Miracell Co., Ltd., which supplies its stem cell extraction medical device, “Smart Mcell,” and blood and bone marrow kits to over 600 hospitals and clinics worldwide, has launched “Celldoc,” a stem cell treatment community platform.
With the launch of Celldoc, a stem cell community platform connecting B2B (business-to-business) and B2C (business-to-consumer) channels, patients can access accurate information on stem cell treatments and easily access everything from stem cell clinic appointments to treatment.
Miracell developed the app in response to the growing consumer interest in regenerative medicine and the increasing efficacy and safety of stem cell treatments driven by new medical technologies. Despite this, demand has grown, leading to a lack of relevant information. Miracell CEO Shin Hyun-soon explained, “Since 2007, Miracell has contributed to the nation’s health with stem cell reverse aging treatments for rare and intractable diseases, hair loss, skin, and plastic surgery. Many people still travel overseas to Japan and China for stem cell injections, but many overseas locations use cultured cells, which carry risks such as cell mutation and contamination.
Safety must be a top priority when choosing a treatment that uses freshly extracted, concentrated cells directly injected into the body without culturing them.” He added, “
We have launched the first stem cell-specific app to provide medical consumers with verified stem cell treatment information.”
Celldoc, which stands for “Cell Doctor,” is a personalized total healthcare solution that contains all the information on stem cell treatments.
It offers answers to questions about stem cells, remote consultations with medical professionals, and convenient reservations at each hospital.
Patients can directly order kits for stem cell treatment and skin care procedures through the app, and receive the treatment at a designated hospital.
All of Celldoc’s affiliated hospitals use proven stem cells and adhere to the principle of quantitative treatment.
These hospitals utilize the “Smart M-Cell” stem cell extraction system developed by Miracell and its dedicated kits.
Smart M-Cell has undergone an equivalence evaluation with the stem cell extraction equipment from Smart Prep, the US company that also treated golfer Tiger Woods’ knee, and has received approval from the Ministry of Food and Drug Safety.
The treatment utilizes highly concentrated stem cells with a cell viability rate of over 99%, along with at least five multi-cell components essential for regeneration, including growth factors, ensuring safety.
CEO Shin stated, “Hospitals and clinics using Smart M-Cell, known for its high cell viability and recovery rates, are sharing their medical information on Celldoc, raising high expectations from both doctors and consumers.”
“The Celldoc platform lists over 500 hospitals and clinics, categorized by region and symptom, and connects patients directly to the appropriate hospital during consultations. This system will reduce indiscriminate medical shopping and popularize stem cell treatment.”
Through Celldoc, patients can receive the same high-quality stem cell treatment at any hospital nationwide.
The app provides preemptive information on stem cell treatment, enhancing patient understanding and enabling efficient medical services.
Celdoc offers personalized treatments for knee arthritis, skin, hair loss, anti-aging, and more, utilizing SmartMcell’s unique stem cell extraction. Furthermore, Celldoc-affiliated hospitals and clinics can order kits and check inventory in real time through the app.
Celdoc membership is free, and group purchases offer hospitals benefits. The app is available for Android, with iOS scheduled to launch in about a month.
Miracell’s stem cell effects are recognized internationally, fueling a boom in preventive medicine.
Dr. Theodoropoulos Ilias, a hematologist from Greece, presented the therapeutic effects of SmartMcell at the “2024 IV CONGRESO SEMDOR VALENCIA,” hosted by the Spanish Society of Pain Medicine.
Dr. Ilias stated that he has personally treated over 400 patients, including those receiving intravenous injections, using SmartMcell over the past year, demonstrating excellent treatment effects and plans to write a paper based on these findings.
Currently, Miracell shares stem cell information with hospitals in over 40 countries using SmartMcell, including Greece, Austria, and Spain, through the medical platform “Celphia Global Platform (CGP).”
Miracell plans to upgrade Celldoc to a global medical system by connecting with hospitals and clinics in each country.
CEO Shin stated, “Celdoc also serves as a medical tourism platform, which is expected to attract many international patients to our member hospitals.
I recently met with the president of the Indonesian Women Entrepreneurs Association, and many member companies expressed their willingness to visit Korea for medical tourism through Celldoc.
We anticipate that this will be the starting point for many international patients seeking stem cell treatment in Korea. We aim to reach over 5,000 hospitals worldwide, and we will expand Celldoc into a world-class medical platform and global app.”
Meanwhile, Miracell is a leading company in stem cell and cell therapy, holding the most approvals from the Ministry of Food and Drug Safety.
In July 2023, the government directly registered a new medical technology for intra-articular injection of bone marrow aspirate concentrate for knee osteoarthritis using Smart Mcell, recognizing its efficacy.
In 2012, Miracell also registered stem cell treatments for cartilage defects, and in 2013, for acute myocardial infarction and critical limb ischemia, and these treatments are now being used in hospitals.
Source: Dong-A Ilbo (https://www.donga.com/news/Health/article/all/20250415/131414005/2)